{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.7","upperLimit":"12.9","value":"10.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.\n\nlapatinib ditosylate: Given orally\n\ncapecitabine: Given orally","id":"OG000","title":"Lapatinib Ditosylate and Capecitabine"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"5 years","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Months"}